Immix Biopharma’s (IMMX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note released on Monday morning,Benzinga reports. They currently have a $7.00 price target on the stock.

Immix Biopharma Stock Down 1.3 %

Shares of NASDAQ:IMMX opened at $2.25 on Monday. The company’s 50-day moving average price is $2.01 and its 200 day moving average price is $1.95. The company has a market cap of $61.89 million, a PE ratio of -2.65 and a beta of 0.27. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $6.67.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, equities analysts anticipate that Immix Biopharma will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Immix Biopharma stock. Invst LLC bought a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned 0.10% of Immix Biopharma at the end of the most recent quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.